News
Cellegy Pharmaceuticals (CLGY) Appoints Agis To Distribute Rectogesic(R) In Israel
Huntingdon Valley, Penn. / -FirstCall/ -- Cellegy Pharmaceuticals, Inc. announced today that it has appointed Agis Commercial Agencies Ltd. as its exclusive distributor for Rectogesic(R) nitroglycerin ointment in Israel. Agis will file for regulatory approval utilizing the European Common Technical Document that provided the basis for approval of Rectogesic by 20 European countries earlier this year.
Agis, which was acquired by Perrigo last year, is a diversified pharmaceutical company with operations in the production, import and marketing of major ethical drugs in Israel. The company manufactures under license and also imports pharmaceuticals, representing several major pharmaceutical companies in Israel, including: Schering AG, Bayer Diagnostics, Solvay, and Bayer AG.
"We are pleased to bring Rectogesic to market in Israel through a partnership with Agis," said Richard C. Williams, Cellegy's Chairman and interim CEO. "Israeli clinical investigators played a significant role in the trials that led to approval for Rectogesic in Europe, and we wanted to find the right distributor to bring the product to market. Rectogesic fits well with the target audience currently called on by Agis, and both Agis and Cellegy expect rapid commercial uptake of the product."
Rectogesic ointment, 0.4% is currently being sold by ProStrakan Ltd., Cellegy's licensee in Europe, for the treatment of anal fissure. The product was launched in the UK during the second quarter of 2005 and through the Mutual Recognition Process, is now approved in 20 countries in Europe. Sales continue to exceed expectations.